

In the format provided by the authors and unedited.

# A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat <sup>1,2</sup>, Daniel Stadlbauer <sup>1</sup>, Shirin Strohmeier<sup>1,3</sup>, Thi H. O. Nguyen <sup>4</sup>,  
Veronika Chromikova<sup>1</sup>, Meagan McMahon<sup>1</sup>, Kaijun Jiang<sup>1</sup>, Guha Asthagiri Arunkumar <sup>1,2</sup>,  
Denise Jurczynszak<sup>1,2</sup>, Jose Polanco<sup>1,5</sup>, Maria Bermudez-Gonzalez<sup>1</sup>, Giulio Kleiner <sup>1</sup>, Teresa Aydillo<sup>1,6</sup>,  
Lisa Miorin<sup>1,6</sup>, Daniel S. Fierer <sup>7</sup>, Luz Amarilis Lugo<sup>7</sup>, Erna Milunka Kojic<sup>7</sup>, Jonathan Stoeber <sup>8</sup>,  
Sean T. H. Liu<sup>1,7,9,10</sup>, Charlotte Cunningham-Rundles<sup>11,12</sup>, Philip L. Felgner<sup>13</sup>, Thomas Moran<sup>1</sup>,  
Adolfo García-Sastre <sup>1,6,7,14</sup>, Daniel Caplivski<sup>15</sup>, Allen C. Cheng<sup>16</sup>, Katherine Kedzierska <sup>4</sup>,  
Olli Vapalahti<sup>17,18,19</sup>, Jussi M. Hepojoki <sup>17,20</sup>, Viviana Simon<sup>1,6,7</sup> and Florian Krammer <sup>1</sup> 

<sup>1</sup>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>2</sup>Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>3</sup>Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria. <sup>4</sup>Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. <sup>5</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>6</sup>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>7</sup>Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>8</sup>Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>9</sup>Department of Medicine, Mount Sinai Queens, Astoria, NY, USA. <sup>10</sup>Division of Hospital Medicine, Mount Sinai Health System, New York, NY, USA. <sup>11</sup>Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>12</sup>Department of Pediatrics, the Icahn School of Medicine at Mount Sinai, NY, USA. <sup>13</sup>Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA. <sup>14</sup>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>15</sup>Travel Medicine Program, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>16</sup>School of Public Health and Preventive Medicine, Monash University and Infection Prevention and Healthcare Epidemiology Unit Alfred Health, Melbourne, Victoria, Australia. <sup>17</sup>Department of Virology, Medicum, University of Helsinki, Helsinki, Finland. <sup>18</sup>Veterinary Biosciences, Veterinary Faculty, University of Helsinki, Helsinki, Finland. <sup>19</sup>Department of Virology and Immunology, Helsinki University Hospital (HUSLAB), Helsinki, Finland. <sup>20</sup>Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland. ✉e-mail: [florian.krammer@mssm.edu](mailto:florian.krammer@mssm.edu)

**Supplementary Table 1: Convalescent samples from COVID19 patients**

Sample #	Sample taken post day symptom onset	Severity
1	20	ND
2	4	ND
3	3	ND
4	6	ND
5	8	Severe
6	11	Severe
7	15	Severe
8	7	Severe
9	10	Severe
10	13	Severe
11	17	Severe
12	20	Mild
13	20	Mild
14	30	Mild
15	21	Mild
16	ND	Asymptomatic